期刊
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
卷 12, 期 8, 页码 1246-+出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cgh.2014.02.016
关键词
Health-Related Quality Of Life; Ulcerative Colitis; Crohn's Disease; CDAI
资金
- Merck
- Abbott
- Janssen
- Genentech
- Mitsubishi
- Ferring
- Norgine
- Tillots
- Vifor
- Shire
- Therakos
- Pharmacosmos
- Pilege
- BMS
- UCB-pharma
- Hospira
- Takeda
- ActoGeniX NV
- AGI Therapeutics, Inc
- Alba Therapeutics Corporation
- Albireo
- Alfa Wasserman
- Amgen
- AM-Pharma BV
- Anaphore
- Astellas Pharma
- Athersys, Inc
- Atlantic Healthcare Limited
- Aptalis
- BioBalance Corporation
- Boehringer-Ingelheim, Inc
- Bristol Meyers Squibb
- Celgene
- Celek Pharmaceuticals
- Cellerix SL
- Cerimon Pharmaceuticals
- ChemoCentryx
- CoMentis
- Cosmo Technologies
- Coronado Biosciences
- Cytokine Pharmasciences
- Eagle Pharmaceuticals
- Eisai Medical Research, Inc
- Elan Pharmaceuticals
- EnGene, Inc
- Eli Lilly
- Enteromedics
- Exagen Diagnostics, Inc
- Ferring Pharmaceuticals
- Flexion Therapeutics, Inc
- Funxional Therapeutics Limited
- Genzyme Corporation
- Roche
- Gilead Sciences
- Given Imaging
- Glaxo Smith Kline
- Human Genome Sciences
- Ironwood Pharmaceuticals
- KaloBios Pharmaceuticals, Inc
- Lexicon Pharmaceuticals
- Lycera Corporation
- Meda Pharmaceuticals
- Merck Research Laboratories
- MerckSerono
- Millennium Pharmaceuticals
- Nisshin Kyorin Pharmaceuticals Co, Ltd
- Novo Nordisk A/S
- NPS Pharmaceuticals
- Optimer Pharmaceuticals
- Orexigen Therapeutics, Inc
- PDL Biopharma
- Pfizer
- Procter and Gamble
- Prometheus Laboratories
- ProtAb Limited
- Purgenesis Technologies, Inc
- Receptos
- Relypsa, Inc
- Salient Pharmaceuticals
- Salix Pharmaceuticals, Inc
- Santarus
- Schering Plough Corporation
- Shire Pharmaceuticals
- Sigmoid Pharma Limited
- Sirtris Pharmaceuticals, Inc (a GSK company)
- S.L.A. Pharma (UK) Limited
- Targacept
- Teva Pharmaceuticals
- Tillotts Pharma AG
- TxCell SA
- UCB Pharma
- Viamet Pharmaceuticals
- Vascular Biogenics Limited
- Warner Chilcott UK Limited
- Novartis
- Procter and Gamble Pharmaceuticals
The Food and Drug Administration (FDA) is moving from the Crohn's Disease Activity Index to patient-reported outcomes (PROs) and objective measures of disease, such as findings from endoscopy. PROs will become an important aspect of assessing activity of inflammatory bowel disease (IBD) and for labeling specific drugs for this disease. PROs always have been considered in the management of patients with rheumatoid arthritis or multiple sclerosis, and have included measurements of quality of life, disability, or fatigue. Several disease-specific scales have been developed to assess these PROs and commonly are used in clinical trials. Outcomes reported by patients in clinical trials of IBD initially focused on quality of life, measured by the Short-Form 36 questionnaire or disease-specific scales such as the Inflammatory Bowel Disease Questionnaire or its shorter version. Recently considered factors include fatigue, depression and anxiety, and work productivity, as measured by the Functional Assessment Chronic Illness Therapy-Fatigue, the Hospital Anxiety Depression, and the Work Productivity Activity Impairment Questionnaire, respectively. However, few data are available on how treatment affects these factors in patients with IBD. Although disability generally is recognized in patients with IBD, it is not measured. The international IBD disability index currently is being validated. None of the PROs currently used in IBD were developed according to FDA guidance for PRO development. PROs will be a major primary end point of future trials. FDA guidance is needed to develop additional PROs for IBD that can be incorporated into trials, to better compare patients' experience with different therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据